Monday, September 16, 2024 9/16/2024

Maternal Marijuana Use During Pregnancy, Marijuana Legalization, and Adverse Obstetrical and Neonatal Outcomes: A 12-year Cohort Study

Award Number: R01DA047405
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

PROJECT SUMMARY/ABSTRACT The COVID-19 pandemic has high potential to lead to broad increases in substance use among pregnant women (e.g., via increased social isolation and loneliness due to extensive “shelter-in-place” orders, psychological and financial distress, fear of infection). Further, smoking, vaping and other substance use may increase risk for COVID-19 and its more serious complications; pregnant women are an ideal population to study the effects of substance use on COVID-19 risk and illness progression as they have reduced immune functioning and, in Kaiser Permanente Northern California (KPNC), are routinely screened for substance use as part of standard prenatal care. The proposed study represents an unparalleled opportunity to efficiently leverage rich, valid and contemporary prenatal substance use data by self-report and urine toxicology testing from our existing R01 study (DA047405) in innovative ways. For Aim 1, we take advantage of a unique natural experiment using interrupted time series analyses to examine whether the COVID-19 pandemic is associated with broad increases in prenatal substance use overall and among vulnerable subsets of pregnant women (e.g., those with prenatal depression, low socioeconomic status (SES)) using data from ~200,000 pregnancies universally screened for prenatal substance from January 2018 to December 2021. For Aim 2, we will conduct a retrospective and prospective longitudinal cohort study of ~100,000 pregnant women from January 2020 to December 2021, to examine whether substance use in the year before pregnancy, and during pregnancy, is associated with increased risk of COVID-19 onset and severity of illness. COVID-19 data will be ascertained from KPNC’s innovative tracking and surveillance system which includes laboratory confirmed COVID-19 infection, persons under investigation with symptoms who have not yet been tested, symptom severity, medical complications, and mortality. These data will be efficiently linked to prenatal substance use data ascertained for the parent grant using the electronic health record with high generalizability and a large sample size. Our results will provide sorely needed and generalizable data on the impact of this pandemic on rates of prenatal substance use and the impact of substance use on COVID-19 onset and progression. Results will guide preventive measures, public health interventions, and health services, and can inform best practices to protect pregnant women against potential long-term health consequences of this pandemic.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $625,938 )
2023	2023	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Drug Abuse and Addiction Research Programs	000	5	3/28/2023	NON-COMPETING CONTINUATION	$625,938
														Subtotal = $625,938

Issue Date FY: 2022 ( Subtotal = $625,522 )
2022	2022	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Drug Abuse and Addiction Research Programs	000	4	4/21/2022	NON-COMPETING CONTINUATION	$625,522
														Subtotal = $625,522

Issue Date FY: 2021 ( Subtotal = $809,599 )
2021	2021	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Drug Abuse and Addiction Research Programs	000	3	4/21/2021	NON-COMPETING CONTINUATION	$809,599
														Subtotal = $809,599

Issue Date FY: 2020 ( Subtotal = $810,266 )
2020	2020	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Drug Abuse and Addiction Research Programs	000	2	4/24/2020	NON-COMPETING CONTINUATION	$648,158
2020	2020	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Drug Abuse and Addiction Research Programs	001	2	6/26/2020	SUPPLEMENT FOR EXPANSION	$162,108
														Subtotal = $810,266

Issue Date FY: 2019 ( Subtotal = $662,872 )
2019	2019	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Drug Abuse and Addiction Research Programs	000	1	6/10/2019	NEW	$662,872
														Subtotal = $662,872

Grand Total All Awards = $3,534,197

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Maternal Marijuana Use During Pregnancy, Marijuana Legalization, and Adverse Obstetrical and Neonatal Outcomes: A 12-year Cohort Study

Award Number: R01DA047405

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer